Flipping the wound that doesn't heal: The upside of coagulation in cancer

Blood

Volumn 113, Issue 20, 2009, Pages 4827-4828

  Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; BAVITUXIMAB; BEVACIZUMAB; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; DRUG CARRIER; FIBRONECTIN; HYBRID PROTEIN; INTEGRIN; PEPTIDE DERIVATIVE; SORAFENIB; SUNITINIB; THROMBOPLASTIN; TRUNCATED TISSUE FACTOR; TRUNCATED TISSUE FACTOR ASPARAGINYLGLYCYLARGININE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR TARGETING AGENT;

ANTIANGIOGENIC ACTIVITY; BLOOD CLOTTING; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; HUMAN; LOW DRUG DOSE; NOTE; PRIORITY JOURNAL; PROGNOSIS; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR THROMBUS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WOUND HEALING;

EID: 70449411148     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-207316     Document Type: Note

References (7)

1. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer. 2006;6:626-635. (Pubitemid 44140860)
2. Tozer GM, Kanthou C, Baguley BC. Disrupting tumor blood vessels. Nat Rev Cancer. 2005;5:423-435.
3. Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res. 2005;11:1551-1562. (Pubitemid 40315240)
4. Belt RJ, Leite C, Haas CD, Stephens RL. Incidence of hemorrhagic complications in patients with cancer. JAMA. 1978;239:2571-2574. (Pubitemid 8393889)
5. Chang HY, Nuyten DSA, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A. 2005;102:3738-3743.
6. Bieker R, Kessler T, Schwöppe C, et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood. 2009;113:5019-5027.
7. Kessler T, Bieker R, Padró T, et al. Inhibition of tumor growth byRGDpeptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res. 2005;11:6317-6324. (Pubitemid 41262963)